The safety of BCG revaccination in the context of COVID-19

References

• Rousseau MC, Parent ME, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr Allergy Immunol. 2008;19(5):438–4. doi:10.1111/j.1399-3038.2007.00669.x.
   PubMed Web of Science ®Google Scholar
• Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol. 2015;98(3):347–56. doi:10.1189/jlb.5RI0315-096R.
   PubMed Web of Science ®Google Scholar
• Luca S, Mihaescu T. History of BCG vaccine. Maedica (Bucur). 2013;8:53–8.
   PubMedGoogle Scholar
• Wardhana DE, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43:185–90.
   PubMedGoogle Scholar
• Sylvester RJ, van der MA, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–70. doi:10.1016/S0022-5347(05)64273-5.
   PubMed Web of Science ®Google Scholar
• Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. MedRxiv. 2020;2020:2020.03. 24.20042937.
   Google Scholar
• Joy M, Malavika B, Asirvatham ES, Sudarsanam TD, Jeyaseelan L. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries. Clin Epidemiol Global Health. 2021;9:202–3. doi:10.1016/j.cegh.2020.08.015.
   PubMed Web of Science ®Google Scholar
• Trunk G, Davidović M, Bohlius J. Non-specific effects of Bacillus Calmette-Guérin: a systematic review and meta-analysis of randomized controlled trials. Vaccines (Basel). 2023;11(1):121. doi:10.3390/vaccines11010121.
   PubMed Web of Science ®Google Scholar
• Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395(10236):1545–6. doi:10.1016/S0140-6736(20)31025-4.
   PubMed Web of Science ®Google Scholar
• Wen J, Liu Q, Tang D, He JQ. Efficacy of BCG vaccination against COVID-19: systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2023;12(3):1154. doi:10.3390/jcm12031154.
   PubMed Web of Science ®Google Scholar
• Dourado I, Rios MH, Pereira SM, Cunha SS, Ichihara MY, Goes JC, Rodrigues LC, Bierrenbach AL, Barreto ML. Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Int J Tuberc Lung Dis. 2003;7:399–402.
   PubMed Web of Science ®Google Scholar
• Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, et al. Prevention of M. tuberculosis infection with H4: IC31 vaccine or BCG revaccination. N Engl J Med. 2018;379(2):138–49. doi:10.1056/NEJMoa1714021.
   PubMed Web of Science ®Google Scholar
• Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom WA, Johnson JL, et al. Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine. 2014;32(31):3982–8. doi:10.1016/j.vaccine.2014.04.084.
   PubMed Web of Science ®Google Scholar
• Knol MJ, Groenwold RHH, Grobbee DE. P-values in baseline tables of randomized controlled trials are inappropriate but still common in high impact journals. Eur J Prev Cardiol. 2012;19(2):231–2. doi:10.1177/1741826711421688.
   PubMed Web of Science ®Google Scholar
• Cunha AJ, Sant’anna CC, Mannarino R, Labanca TC, Ferreira S, March MF. Adverse effects of BCG revaccination: a report on 13 cases from Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2002;6:1110–13.
   PubMed Web of Science ®Google Scholar
• Fjällbrant H, Ridell M, Larsson LO. Primary vaccination and revaccination of young adults with BCG: a study using immunological markers. Scand J Infect Dis. 2007;39(9):792–8. doi:10.1080/00365540701367777.
   PubMed Web of Science ®Google Scholar
• El Ouazzani H, Lamsyah H, Alioua Z, Rhorfi I, Rguibi M, Ghfir M, Abid A, Sedrati O, Alaoui-Tahiri K. Complications de la revaccination par le BCG: 12 observations. Annales de Dermatologie et de Vénéréologie. 2007;134(2):129–32. doi:10.1016/S0151-9638(07)91603-8.
   PubMedGoogle Scholar
• Villanueva P, Wadia U, Crawford N, Messina NL, Kollmann TR, Lucas M, Manning L, Richmond P, Pittet LF, Curtis N, et al. Revaccination with Bacille Calmette-Guérin (BCG) is associated with an increased risk of abscess and lymphadenopathy. NPJ Vaccines. 2022;7(1):6. doi:10.1038/s41541-021-00421-5.
   PubMed Web of Science ®Google Scholar
• Roh EJ, Lee YK, Lee MH, Kim M-K, Kim TE, Lee SG, Chung EH. Investigation of adverse events following bacille Calmette-Guérin immunization using immunization safety surveillance system in Korea centers for disease control and prevention. Clin Exp Vaccine Res. 2020;9(2):133–45. doi:10.7774/cevr.2020.9.2.133.
   PubMed Web of Science ®Google Scholar
• Richardus R, van Hooij A, van den Eeden SJ, Wilson L, Alam K, Richardus JH, Geluk A. BCG and adverse events in the context of leprosy. Front Immunol. 2018;9:629. doi:10.3389/fimmu.2018.00629.
   PubMed Web of Science ®Google Scholar
• Yadav T, Kumar S, Mishra G, Saxena SK. Tracking the COVID-19 vaccines: the global landscape. Hum Vaccin Immunother. 2023;19(1):2191577. doi:10.1080/21645515.2023.2191577.
   PubMed Web of Science ®Google Scholar